Log in
NASDAQ:RGNX

REGENXBIO News Headlines

$34.84
-2.21 (-5.96 %)
(As of 11/30/2020 12:00 AM ET)
Add
Compare
Today's Range
$34.52
Now: $34.84▼
$37.14
50-Day Range
$27.03
MA: $31.65▼
$37.05
52-Week Range
$20.03
Now: $34.84▼
$54.97
Volume363,625 shs
Average Volume417,888 shs
Market Capitalization$1.30 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.95

Headlines

REGENXBIO (NASDAQ RGNX) News Headlines Today

Source:
SourceHeadline
BidaskClub Upgrades REGENXBIO (NASDAQ:RGNX) to "Sell"BidaskClub Upgrades REGENXBIO (NASDAQ:RGNX) to "Sell"
marketbeat.com - October 27 at 2:14 AM
Regenxbio (NASDAQ:RGNX) Price Target Lowered to $79.00 at BarclaysRegenxbio (NASDAQ:RGNX) Price Target Lowered to $79.00 at Barclays
marketbeat.com - September 24 at 7:42 AM
Regenxbio (NASDAQ:RGNX) Downgraded by BidaskClub to "Strong Sell"Regenxbio (NASDAQ:RGNX) Downgraded by BidaskClub to "Strong Sell"
marketbeat.com - August 22 at 2:19 AM
REGENXBIO (RGNX) Shares Cross Above 200 DMA - NasdaqREGENXBIO (RGNX) Shares Cross Above 200 DMA - Nasdaq
nasdaq.com - November 16 at 3:09 PM
Kodiak Sciences (NASDAQ:KOD) & REGENXBIO (NASDAQ:RGNX) Financial SurveyKodiak Sciences (NASDAQ:KOD) & REGENXBIO (NASDAQ:RGNX) Financial Survey
americanbankingnews.com - November 15 at 9:19 PM
REGENXBIO (NASDAQ:RGNX) Price Target Cut to $51.00 by Analysts at Morgan StanleyREGENXBIO (NASDAQ:RGNX) Price Target Cut to $51.00 by Analysts at Morgan Stanley
americanbankingnews.com - November 11 at 1:29 PM
REGENXBIO Announces Presentations at the American Academy of Ophthalmology 2020 Annual Meeting - PRNewswireREGENXBIO Announces Presentations at the American Academy of Ophthalmology 2020 Annual Meeting - PRNewswire
prnewswire.com - November 11 at 10:40 AM
Clearside Biomedical Announces Third Quarter 2020 Financial Results and Provides Corporate Update - StreetInsider.comClearside Biomedical Announces Third Quarter 2020 Financial Results and Provides Corporate Update - StreetInsider.com
streetinsider.com - November 11 at 5:40 AM
Clearside Biomedical Announces Third Quarter 2020 Financial Results and Provides Corporate Update - Yahoo FinanceClearside Biomedical Announces Third Quarter 2020 Financial Results and Provides Corporate Update - Yahoo Finance
finance.yahoo.com - November 10 at 6:17 PM
REGENXBIO Announces Presentations at the American Academy of Ophthalmology 2020 Annual Meeting - Yahoo FinanceREGENXBIO Announces Presentations at the American Academy of Ophthalmology 2020 Annual Meeting - Yahoo Finance
finance.yahoo.com - November 10 at 1:16 PM
REGENXBIO Announces Presentations at the American Academy of Ophthalmology 2020 Annual MeetingREGENXBIO Announces Presentations at the American Academy of Ophthalmology 2020 Annual Meeting
finance.yahoo.com - November 10 at 8:15 AM
REGENXBIO Inc. Just Beat Earnings Expectations: Heres What Analysts Think Will Happen Next - Yahoo FinanceREGENXBIO Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next - Yahoo Finance
finance.yahoo.com - November 6 at 12:25 PM
REGENXBIO Inc. Just Beat Earnings Expectations: Heres What Analysts Think Will Happen NextREGENXBIO Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
finance.yahoo.com - November 6 at 12:25 PM
REGENXBIO to Present at Upcoming Investor Conferences - Yahoo FinanceREGENXBIO to Present at Upcoming Investor Conferences - Yahoo Finance
finance.yahoo.com - November 6 at 2:25 AM
Regenxbio (RGNX) Surpasses Q3 Earnings and Revenue Estimates - Yahoo FinanceRegenxbio (RGNX) Surpasses Q3 Earnings and Revenue Estimates - Yahoo Finance
finance.yahoo.com - November 4 at 10:43 PM
Regenxbio Inc. (RGNX) Q3 2020 Earnings Call Transcript - Motley FoolRegenxbio Inc. (RGNX) Q3 2020 Earnings Call Transcript - Motley Fool
fool.com - November 4 at 10:43 PM
Recap: Regenxbio Q3 EarningsRecap: Regenxbio Q3 Earnings
finance.yahoo.com - November 4 at 10:43 PM
Regenxbio (RGNX) Surpasses Q3 Earnings and Revenue EstimatesRegenxbio (RGNX) Surpasses Q3 Earnings and Revenue Estimates
finance.yahoo.com - November 4 at 10:43 PM
Regenxbio Inc. (RGNX) Q3 2020 Earnings Call TranscriptRegenxbio Inc. (RGNX) Q3 2020 Earnings Call Transcript
finance.yahoo.com - November 4 at 10:43 PM
Regenxbio (RGNX) Tops Q3 EPS by $1.24, Revenues Beat - StreetInsider.comRegenxbio (RGNX) Tops Q3 EPS by $1.24, Revenues Beat - StreetInsider.com
streetinsider.com - November 4 at 5:42 PM
REGENXBIO, Inc. to Host Earnings Call - Yahoo FinanceREGENXBIO, Inc. to Host Earnings Call - Yahoo Finance
finance.yahoo.com - November 4 at 5:42 PM
REGENXBIO, Inc. to Host Earnings CallREGENXBIO, Inc. to Host Earnings Call
finance.yahoo.com - November 4 at 5:42 PM
REGENXBIO Reports Third Quarter 2020 Financial Results and Operational HighlightsREGENXBIO Reports Third Quarter 2020 Financial Results and Operational Highlights
finance.yahoo.com - November 4 at 5:42 PM
Regenxbio Q3 Earnings PreviewRegenxbio Q3 Earnings Preview
seekingalpha.com - November 4 at 7:42 AM
Is a Disappointment in Store for Tilrays (TLRY) Q3 Earnings? - NasdaqIs a Disappointment in Store for Tilray's (TLRY) Q3 Earnings? - Nasdaq
nasdaq.com - November 3 at 8:08 PM
Corlieve Therapeutics SAS Closes Seed Financing to Develop Therapies for Severe Neurological Conditions - PRNewswireCorlieve Therapeutics SAS Closes Seed Financing to Develop Therapies for Severe Neurological Conditions - PRNewswire
prnewswire.com - November 2 at 8:16 AM
REGENXBIO To Host Conference Call on November 4 to Discuss Third Quarter 2020 Financial Results and Recent Operational Highlights - Yahoo FinanceREGENXBIO To Host Conference Call on November 4 to Discuss Third Quarter 2020 Financial Results and Recent Operational Highlights - Yahoo Finance
finance.yahoo.com - October 28 at 5:35 PM
REGENXBIO To Host Conference Call on November 4 to Discuss Third Quarter 2020 Financial Results and Recent Operational HighlightsREGENXBIO To Host Conference Call on November 4 to Discuss Third Quarter 2020 Financial Results and Recent Operational Highlights
finance.yahoo.com - October 28 at 5:35 PM
Regenxbio earns $80M milestone from NovartisRegenxbio earns $80M milestone from Novartis
seekingalpha.com - October 27 at 7:57 PM
Investors Who Bought REGENXBIO (NASDAQ:RGNX) Shares Five Years Ago Are Now Up 77% - Yahoo FinanceInvestors Who Bought REGENXBIO (NASDAQ:RGNX) Shares Five Years Ago Are Now Up 77% - Yahoo Finance
finance.yahoo.com - October 27 at 2:56 PM
REGENXBIO to Receive $80.0 Million Milestone Payment from Novartis AGREGENXBIO to Receive $80.0 Million Milestone Payment from Novartis AG
finance.yahoo.com - October 27 at 2:56 PM
Investors Who Bought REGENXBIO (NASDAQ:RGNX) Shares Five Years Ago Are Now Up 77%Investors Who Bought REGENXBIO (NASDAQ:RGNX) Shares Five Years Ago Are Now Up 77%
finance.yahoo.com - October 27 at 2:56 PM
Do Hedge Funds Love Regenxbio Inc (RGNX)?Do Hedge Funds Love Regenxbio Inc (RGNX)?
finance.yahoo.com - October 15 at 3:10 PM
Maryland Tech Council Announces Winners of 32nd Annual Industry Awards - StreetInsider.comMaryland Tech Council Announces Winners of 32nd Annual Industry Awards - StreetInsider.com
streetinsider.com - October 14 at 5:23 PM
Regenxbio RGX-121 Clinical Program, And Other News: The Good, Bad And Ugly Of BiopharmaRegenxbio RGX-121 Clinical Program, And Other News: The Good, Bad And Ugly Of Biopharma
seekingalpha.com - October 6 at 2:33 PM
Regenxbio Advances Clinical Program, And Other News: The Good, Bad And Ugly Of Biopharma - Seeking AlphaRegenxbio Advances Clinical Program, And Other News: The Good, Bad And Ugly Of Biopharma - Seeking Alpha
seekingalpha.com - October 3 at 12:16 PM
REGENXBIO to enroll more patients in mid-stage study for MPS II gene therapy - Seeking AlphaREGENXBIO to enroll more patients in mid-stage study for MPS II gene therapy - Seeking Alpha
seekingalpha.com - September 30 at 2:26 PM
REGENXBIO Announces Continued Progress and Expansion of Clinical Development Program for RGX-121 for the Treatment of Mucopolysaccharidosis Type II (MPS II) - PRNewswireREGENXBIO Announces Continued Progress and Expansion of Clinical Development Program for RGX-121 for the Treatment of Mucopolysaccharidosis Type II (MPS II) - PRNewswire
prnewswire.com - September 30 at 9:20 AM
Global Mucopolysaccharidosis (MPS) Treatment Market to Surpass US$ 3014.9 Million by 2027, Says Coherent Market Insights (CMI) - Business WireGlobal Mucopolysaccharidosis (MPS) Treatment Market to Surpass US$ 3014.9 Million by 2027, Says Coherent Market Insights (CMI) - Business Wire
businesswire.com - September 22 at 12:00 PM
3 Reasons RBC Capital Thinks the Sarepta Therapeutics (SRPT) Patent Infringement Suit is not Meaningful - streetinsider.com3 Reasons RBC Capital Thinks the Sarepta Therapeutics (SRPT) Patent Infringement Suit is not Meaningful - streetinsider.com
streetinsider.com - September 18 at 10:45 AM
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating REGENXBIO Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors - Yahoo FinanceSHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating REGENXBIO Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors - Yahoo Finance
finance.yahoo.com - September 14 at 7:59 PM
Regenxbio: More Robust Data For Wet AMDRegenxbio: More Robust Data For Wet AMD
seekingalpha.com - September 13 at 8:30 AM
Clearside Biomedicals Licensing Partner Doses First Patient in its Phase 2 Gene Therapy Trial Using SCS Microinjector® for Suprachoroidal Delivery - StreetInsider.comClearside Biomedical's Licensing Partner Doses First Patient in its Phase 2 Gene Therapy Trial Using SCS Microinjector® for Suprachoroidal Delivery - StreetInsider.com
streetinsider.com - September 10 at 9:51 AM
Regenxbio (RGNX) Reports First Patient Dosing in Phase II AAVIATE Trial of RGX-314 for Treatment of Wet AMD Using Suprachoroidal Delivery - StreetInsider.comRegenxbio (RGNX) Reports First Patient Dosing in Phase II AAVIATE Trial of RGX-314 for Treatment of Wet AMD Using Suprachoroidal Delivery - StreetInsider.com
streetinsider.com - September 10 at 9:51 AM
Dosing underway in Regenxbios mid-stage AAVIATE trial in wet AMDDosing underway in Regenxbio's mid-stage AAVIATE trial in wet AMD
seekingalpha.com - September 9 at 3:46 PM
Clearside Biomedicals Licensing Partner Doses First Patient in its Phase 2 Gene Therapy Trial Using SCS Microinjector® for Suprachoroidal Delivery - GlobeNewswireClearside Biomedical's Licensing Partner Doses First Patient in its Phase 2 Gene Therapy Trial Using SCS Microinjector® for Suprachoroidal Delivery - GlobeNewswire
globenewswire.com - September 9 at 10:45 AM
REGENXBIO Announces Dosing of First Patient in Phase II AAVIATE™ Trial of RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery - PRNewswireREGENXBIO Announces Dosing of First Patient in Phase II AAVIATE™ Trial of RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery - PRNewswire
prnewswire.com - September 9 at 10:45 AM
REGENXBIO Announces Dosing of First Patient in Phase II AAVIATE™ Trial of RGX-314 for the Treatment of Wet AMD Using Suprachoroidal DeliveryREGENXBIO Announces Dosing of First Patient in Phase II AAVIATE™ Trial of RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery
finance.yahoo.com - September 9 at 10:45 AM
Graybug Vision readies IPO - Seeking AlphaGraybug Vision readies IPO - Seeking Alpha
seekingalpha.com - September 5 at 10:40 PM
REGENXBIO to Participate in Upcoming Investor Conferences - Yahoo FinanceREGENXBIO to Participate in Upcoming Investor Conferences - Yahoo Finance
finance.yahoo.com - September 3 at 2:17 PM
REGENXBIO to Participate in Upcoming Investor ConferencesREGENXBIO to Participate in Upcoming Investor Conferences
finance.yahoo.com - September 2 at 5:58 PM
Regenxbio (RGNX) Announces FDA Clearance of IND for Phase II Trial of RGX-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery - StreetInsider.comRegenxbio (RGNX) Announces FDA Clearance of IND for Phase II Trial of RGX-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery - StreetInsider.com
streetinsider.com - August 26 at 6:39 AM
How Does REGENXBIOs (NASDAQ:RGNX) CEO Salary Compare to Peers? - Yahoo FinanceHow Does REGENXBIO's (NASDAQ:RGNX) CEO Salary Compare to Peers? - Yahoo Finance
finance.yahoo.com - August 25 at 1:27 PM
This page was last updated on 12/1/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.